There may be three types of targeted drugs in CRC: anti-EGFR antibodies such as panitumumab and cetuximab; anti-VEGF like such as bevacizumab, ramucirumab and aflibercept; multikinase inhibitors such as regorafenib [106]. This evidence concerns the gene EGFR and colorectal carcinoma.